Modulation of GvHD by suicide-gene transduced donor T lymphocytes: Clinical applications in mismatched transplantation

Cytotherapy

Volumn 7, Issue 2, 2005, Pages 144-149

  Ciceri, Fabio ^a   Bonini, C ^a   Gallo Stampino, C ^b   Bordignon, C ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b MOLMED S P A   (Italy)

Author keywords

Allogeneic transplantation; Gene therapy; HSV TK

Indexed keywords

GANCICLOVIR; NERVE GROWTH FACTOR RECEPTOR; THYMIDINE KINASE; VIRUS VECTOR;

ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RISK; CHRONIC LEUKEMIA; CLINICAL TRIAL; FEASIBILITY STUDY; GENE TRANSFER; GENETIC ENGINEERING; GENETIC MANIPULATION; GENETIC TRANSDUCTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX VIRUS; HLA MATCHING; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; LYMPHOCYTE; MULTIPLE MYELOMA; MYCOSIS; RISK ASSESSMENT; SAFETY; SUICIDE GENE; SUICIDE GENE THERAPY; T CELL DEPLETION; T LYMPHOCYTE; VIRUS INFECTION;

EID: 21044453633     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240510018136     Document Type: Review

References (32)

1. Ringden O, Horowitz MM, Gale RP et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993;270:57-60.
2. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330:827-38.
3. Klingemann HG, Storb R, Fefer A et al. Bone marrow transplantation in patients aged 45 years and older. Blood 1986; 67:770-6.
4. Appelbaum FR. Hematopoietic cell transplantation immunotherapy. Nature 2001;411:385-9.
5. Basara N, Blau IW, Willenbacher W et al. New strategies in the treatment of graft-versus-host disease. Bone Marrow Transplant 2000;25(suppl 2):S12-5.
6. Gaziev D, Galimberti M, Lucarelli G, Polchi P. Chronic graft-versus-host disease: is there an alternative to the conventional treatment? Bone Marrow Transplant 2000;25:689-96.
7. Kolb HJ, Mittermuller J, Clemm CH et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5.
8. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1995;86:2041-50.
9. Mackinnon S, Papadopoulos EP, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia following bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261-8.
10. Collins RH, Shpilberg OJ, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15: 433-44.
11. Porter DL, Connors JM, Van Deerlin VM et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 1999;17: 1234-43.
12. Collins RH Jr, Goldstein S, Giralt S et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000;26:511-6.
13. Schmid C, Schleuning M, Aschan J et al. Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia 2004;18(8):1430-3.
14. Porter DL, Collins RH Jr, Shpilberg O et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant 1999;5:253-61.
15. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004;103:767-76.
16. Dazzi F, Szydlo RM, Craddock C et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000;95:67-71.
17. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic BMT. Blood 1995;86:4337-43.
18. Falkenburg JHF, Wafelman AR, Joosten P et al. Complete remission of accelerated phase CML by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999;94: 1201-8.
19. Bordignon C, Carlostella C, Colombo MP et al. Cell therapy: achievements and perspectives. Haematologica 1999;84:1100-49.
20. Bordignon C, Bonini C. A clinical protocol for gene transfer into peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity in patients affected by recurrent disease after allogeneic bone marrow transplantation. Hum Gen Ther 1995;2:813-9.
21. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-24.
22. Bordignon C, Notarangelo LD, Nobili N et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995;270:470-5.
23. Bonini C, Ciceri F, Marktel S, Bordignon C. Suicide-gene-transduced T-cells for the regulation of the graft-versus-leukemia effect. Vox Sang 1998;74(suppl 2):341-3.
24. Tiberghien P. Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study. Hum Gen Ther 1997;8:615-24.
25. Verzelletti S, Bonini C, Marktel S et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Human Gene Ther 1998;9:2243-51.
26. Ciceri F, Bonini C, Marktel S et al. Long term follow-up in 30 patients receiving HSV-tk transduced donor lymphocytes after allo-BMT. 41th Annual Meeting of the American Society of Hematology, New Orleans, December 3-7. Blood 1999;94(suppl 1):668a.
27. Tiberghien P, Ferrand C, Lioure B et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell depleted allogeneic marrow graft. Blood 2001;97:63-72.
28. Aversa F, Tabilio A, Velardi A et al. Treatment of high risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339:1186-93.
29. Bonini C, Ciceri F, Marktel S et al. Abrogation of GvHD and early immune reconstitution after infusion of HSV-TK engineered donor lymphocytes after haplo-identical hemopoietic stem cell transplantation. Blood 2002;100(suppl 1): 425a.
30. Bonini C, Ciceri F, Lupo-Stanghellini MT et al. A phase II multicenter trial of HSV-TK engineered donor lymphocytes after Haplo-identical HSCT: Early immune reconstitution and abrogation of GvHD. Blood 2004;(suppl 1)104:436a.
31. Baum C, Düllmann J, Li Z et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003;101: 2099-113.
32. Bonini C, Grez M, Traversari C et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 2003;9:367-9.